Pipeline & Success Stories


PARI maintains multiple partnerships for its inhalation systems, under exclusive license agreements in various stages of development and product life cycle.

+ several undisclosed partnerships

Success stories

Lamira® for ARIKAYCE® (amikacin liposome inhalation suspension)

Insmed Incorporated is a global biopharmaceutical company. ARIKAYCE (amikacin liposome inhalation suspension), Insmed’s first commercial product, was approved in the US in 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. ARIKAYCE is the first and only FDA-approved treatment for this patient population. ARIKAYCE is administered via an eFlow® Technology nebuliser system called Lamira.

Further information:




Zirela® for QUINSAIR

San Diego based Mpex Pharmaceuticals Inc. initiated the development of inhaled Levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Raptor Pharmaceuticals Inc. valued QUINSAIR with an upfront payment of $68 million, up to $34 million Raptor shares as well as contingent payments of up to $350 million. Inhaled Levofloxacin is sold under the brand name QUINSAIR in Europe and Canada since 2016 and is administered via an eFlow® Technology nebuliser called Zirela.

Further information:



Tolero® for Vantobra®

Vantobra (Tobramycin 170 mg) is a development and proprietary drug product of PARI Pharma. It is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF). Vantobra is administered via an eFlow® nebuliser handset called Tolero and distributed in some EU countries by PARI owned subsidiaries or selected distribution partners.

Further information:



ColiFin® / Colfinair®

ColiFin / Colfinair (Colistimethate sodium for nebulisation) is a product of PARI Pharma. It is indicated for the management in adult and paediatric of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. The medicinal product is administered via an eFlow®rapid nebuliser handset. ColiFin / Colfinair provide the patient with the saline solution for reconstitution and a new nebuliser handset with each package. This specific drug and device concept is marketed in several countries in the EU and highly accepted providing a unique selling proposition in the treatment of chronic pulmonary infections.

Further information:



LONHALA® MAGNAIR® (glycopyrrolate) Inhalation Solution

LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S. and the first use of the MAGNAIR, which is based on the closed eFlow® Technology nebuliser, developed by PARI Pharma GmbH, to treat COPD. This technology is a virtually silent, portable, closed system nebuliser that is designed to deliver the drug in two to three minutes and allows people to breathe normally while using the device.

Further information:



Featured Videos on LONHALA MAGNAIR


Get a detailed look at the device features of LONHALA MAGNAIR.

Evolution of the nebuliser

Learn about the evolution of nebuliser technology leading up to the MAGNAIR Nebuliser System.


Watch excerpts from an instructional video on how to set-up, administer, and clean LONHALA MAGNAIR which is included in the US approved prescription packaging.

ARIKAYCE is a registered trademark of Insmed Incorporated
Lonhala® is a registered trademark of Sunovion Pharmaceuticals Inc.
SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
QUINSAIR is a trademark of Horizon
eFlow®, eBase®, eLete®, eTrack®, ePort®, eRapid®, Altera®, Zirela®, Tolero®, Magnair®, Lamira®, Vantobra®, ColiFin®, Colfinair® and Vibrent® are registered trademarks of PARI Pharma GmbH

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!